Formycon AG's AGM Approves New Resolutions

Formycon AG held its annual general meeting on June 18, 2025, in Munich, with shareholders approving all proposed resolutions with strong majorities. The Management Board gave a detailed report on the company's robust performance in 2024 and outlined a promising outlook for 2025. They emphasized the company's transition into a commercially oriented biosimilar firm, with increased revenues from global partnerships supporting growth strategies.

The Supervisory Board expanded from five to six members, reflecting the company's growing requirements. Klaus Röhrig was re-elected, and Dr. Graham Keith Dixon was elected as a new member, both receiving significant shareholder support. Wolfgang Essler of ATHOS KG expressed optimism about their roles in advancing Formycon's biosimilar leadership.